NCT06670209尚未招募1 期
A Phase I, Open-label, Fixed-sequence Study to Evaluate the Effect of Repeated Subcutaneous Injections of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese Subjects
Gan and Lee Pharmaceuticals, USA0 个研究点目标入组 32 人开始时间: 2024年10月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 32
- 主要终点
- Cmax,ss
研究概览
简要总结
This is a single-center, open-label, fixed-sequence phase I clinical study to evaluate the effect of multiple subcutaneous injections of GZR18 Injection on the pharmacokinetics of multiple oral doses of metformin hydrochloride tablets.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Overweight/obese Chinese subjects, who voluntarily sign the Informed Consent Form (ICF), can receive subcutaneous injection, fully understand the content, process and possible adverse reactions of the trial, and are able to follow the regulations on contraindications and restrictions specified in this protocol.
- •Male or female, 18 to 50 years of age at signing the ICF (both inclusive).
- •Weight ≥ 50 kg and body mass index (BMI) within 24-33 kg/m2 (both ends inclusive) at screening.
- •Subjects of childbearing potential with no birth plan from the signing of ICF to 3 months after the last dose, willingness to take effective contraceptive measures, and no plan for sperm or ovum donation. Females of childbearing potential must not be lactating and must have negative results of pregnancy tests at screening and Visit 2 (prior to enrollment).
排除标准
- •Subjects with a previous or existing history of heart, liver, kidney, gastrointestinal tract, respiratory system, nervous system, psychiatric disease, malignant tumor and other diseases that are judged by the investigator to have an impact on pharmacokinetics and safety evaluation.
- •History or existing diseases that increase the risk of subjects, such as hypoglycaemia, acute or chronic pancreatitis, pancreatic injury, history of symptomatic gallbladder disease; cholelithiasis with high risk of acute biliary pancreatitis at screening (e.g., silt-like lithiasis, gallbladder ≤ 5 mm in diameter and bile duct stone, etc.).
- •Subjects with previous or existing diseases that significantly affect drug absorption, metabolism or excretion, such as history of active peptic ulcer or haemorrhage, inflammatory bowel disease, abnormal gastric emptying (such as gastric paresis or pyloric stenosis, gastric outlet obstruction), long-term use (continuous for ≥ 1 week) of drugs that affect gastrointestinal motility (including but not limited to domperidone, mosapride, macrolides).
- •Subjects with severe infection or unexplained infection within 4 weeks before screening.
- •Major surgery within 6 months prior to screening, or scheduled surgery or hospitalization during the study.
- •History of drug abuse prior to screening; or positive results for drug abuse at screening.
- •Subjects who used nicotine-containing products within 3 months prior to screening or are screened positive for nicotine in urine.
- •Other factors that make subjects unqualified to participate in this trial as judged by the Investigator.
研究组 & 干预措施
Treatment arm
Experimental
干预措施: GZR18 and metformin (Drug)
结局指标
主要结局
Cmax,ss
时间窗: 24 hours
AUC0-tau
时间窗: 24 hours
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Study the Effect of Omeprazole on AB-106 PharmacokineticsPharmacokinetic StudyNCT05609929Nuvation Bio Inc.24
已完成
1 期
ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy ParticipantsType 2 Diabetes MellitusNCT06293742Eccogene48
已完成
1 期
The Effect of Reduced Liver Function on Selatogrel PharmacokineticsHealthy SubjectsHepatic ImpairmentNCT04406896Viatris Innovation GmbH24
已完成
1 期
A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic ImpairmentHepatic ImpairmentNCT03713242Idorsia Pharmaceuticals Ltd.32
已完成
1 期
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male SubjectsHealthy VolunteersNCT04223232MedDay Pharmaceuticals SA6